Twist Bioscience Corporation
TWST
Rangering i aksjer
#2094
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Aksjekurs
$152.08
Markedsverdi
$10.01B
Endring (1 dag)
6.57%
Endring (1 år)
355.47%
Land
US
Handel Twist Bioscience Corporation (TWST)
Kategori
Healthcare
Inntekter for Twist Bioscience Corporation (TWST)
Inntekter i Jun 2026 TTM: $431.80M
Ifølge de nyeste økonomiske rapportene til Twist Bioscience Corporation er selskapets nåværende inntekter (TTM) $431.80M. I 2024 hadde selskapet inntekter på $312.97M en økning sammenlignet med inntektene i 2023, som var $245.11M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Twist Bioscience Corporation fra 2016 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $431.80M | 14.67% |
| 2025 | $376.57M | 20.32% |
| 2024 | $312.97M | 27.69% |
| 2023 | $245.11M | 20.41% |
| 2022 | $203.57M | 53.83% |
| 2021 | $132.33M | 46.87% |
| 2020 | $90.10M | 65.67% |
| 2019 | $54.39M | 113.89% |
| 2018 | $25.43M | 136.16% |
| 2017 | $10.77M | 374.53% |
| 2016 | $2.27M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $46.34B | 10,630.94% |
US
|
|
| $25.11B | 5,714.52% |
US
|
|
| $2.71B | 526.93% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 1,607.28% |
US
|
